Conversation with Dr. Paul A. Bunn, Jr. in Conjunction with the 2016 Asia Pacific Lung Cancer Conference (APLCC)
“Historically most patients of lung cancer were smokers with advanced lung disease, advanced cancer, and treatments were not very successful. So there was a high degree of pessimism about lung cancer and lung cancer therapy. There was no way to diagnose lung cancer early, and most patients presented with metastatic disease which could not be cured thereby further increasing the pessimism about it,” said Dr. Paul A. Bunn Jr, Distinguished Professor, Division of Medical Oncology, University of Colorado and James Dudley Chair in Lung Cancer Research, USA. Dr. Bunn is also the former President of the International Association for the Study of Lung Cancer (IASLC), former CEO of IASLC, former President of the American Society of Clinical Oncology (ASCO), and the 2016 ASCO David A. Karnofsky Award recipient.
Conversation with Dr. Prakit Vathesatogkit in Conjunction with 2016 Asia Pacific Lung Cancer Conference (APLCC)
“As lung cancer treatment outcomes are difficult and five-year survival is historically low, preventing lung cancer is a top public health priority. Up to 90 percent of lung cancer cases stem from tobacco use. Therefore, effective implementation of evidence-based and comprehensive tobacco control policies will make a huge difference in slashing new cases of lung cancer as well as preventing a large number of other diseases, disabilities, and premature deaths attributed to tobacco use,” said Dr. Prakit Vathesatogkit, Executive Secretary of Action on Smoking and Health Foundation of Thailand.
CHIANG MAI, THAILAND - The 2016 IASLC Asia Pacific Lung Cancer Conference (APLCC) is being organized under the aegis of International Association for the Study of Lung Cancer (IASLC), Thai Society of Clinical Oncology (TSCO), Chiang Mai Lung Cancer Group, Faculty of Medicine at the Chiang Mai University (CMU) and the local organizing committee of APLCC 2016.
DENVER – Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor.
DENVER –A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in non-small cell lung cancer (NSCLC) clinical trials.
DENVER – Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of “Scientific Advances in Lung Cancer 2015” in the May 2016 issue of the IASLC’s Journal of Thoracic Oncology (JTO).